Ipca Mulls Merger Of US Formulations Units

Unichem And Bayshore Could Be Combined Into A Single Entity Under Newly Unveiled Plan

Ipca is considering merging its US generic formulations businesses Bayshore Pharmaceuticals and Unichem Pharmaceuticals USA into a single entity, according to newly-unveiled plans that will be considered by directors in a week’s time.

Disembodied hands putting together two jigsaw pieces
Ipca is considering a merger of Unichem and Bayshore • Source: Shutterstock

US generics players Bayshore Pharmaceuticals and Unichem Pharmaceuticals USA could soon be combined into a single US generic formulations player, under plans unveiled by Bayshore owner and Unichem majority shareholder Ipca Laboratories.

Ipca and Unichem both announced via BSE filings today that a meeting of the board of directors would be held...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business